A Phase 4 interventional study of SPD489 and Placebo in ADHD Specifically With Executive Function Impairment, sponsored by Shire. Completed at 39 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2021-06-09.
Sponsored by Shire (part of Takeda) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity — 1 open to participants now, 1 under way, none of them phase 3. lisdexamfetamine · Attention Deficit Disorder with Hyperactivity.
Among the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, this one is the 15th largest by enrollment, is one of 5 that started in 2010, is one of 23 in phase 4, and was the 26th registered.
1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.
Browse Attention Deficit Disorder with Hyperactivity studies →1 of the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity is open now, in 1 country. Recruiting first, the newest first:
Medical University of Lodz · Sites in Poland
Ages 8 yrs–198 mo
By country, each count listing its studies:
lisdexamfetamine: first FDA approval 2007 (VYVANSE). What it is approved for, and how studies give it, is on its page →
Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 15 · Phase 4 23
First in 2004; this study’s year is marked. 5 started in 2010.
This study's enrollment of 161 is above the median of 71 across 1,437 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.
Median enrollment 48 across the 51 interventional studies. Of the 49 that completed or were terminated, 37 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 51 have an industry lead sponsor. The 10 most frequent:
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
57 studies in Attention Deficit Disorder with Hyperactivity by Takeda: none open now, none under way, none of them phase 3. Of 55 finished, 37 (67%) have results posted.
Among the 57 studies in Attention Deficit Disorder with Hyperactivity by Takeda, this one is the 32nd largest by enrollment of the 53 interventional ones that give a count, is one of 5 that started in 2010, is one of 8 in phase 4, and was the 34th registered.
Takeda’s Attention Deficit Disorder with Hyperactivity studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 57 in Attention Deficit Disorder with Hyperactivity:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to evaluate the efficacy of SPD489 compared to placebo on executive function (self-regulation) behaviors in adults with ADHD who report clinically significant impairment of executive function behavior in their everyday environment, as measured by the self-report Behavior Rating Inventory of Executive Function - Adult Version (BRIEF-A) Global Executive Composite (GEC) T-score.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: SPD489
Other: Placebo
1 capsule per day (30, 50 or 70 mg), daily throughout the double-blind treatment period (10 weeks)
Also known as: Vyvanse
1 capsule per day, daily throughout the double-blind treatment period (10 weeks)
Change From Baseline in Subject-reported Behavior Rating Inventory of Executive Function - Adult Version Global Executive Composite T-score (BRIEF-A GEC T) at up to 10 Weeks
BRIEF-A Global Executive Composite assesses behavioral aspects of executive function. Items are rated 1 (never), 2 (sometimes), and 3 (often). There is no range for a total score. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
Time frame: Baseline and up to 10 weeks
Change From Baseline in Adult ADHD Impact Module (AIM-A) Multi-Item Scales Total Score at up to 10 Weeks
The AIM-A was developed to assess impact of core ADHD symptoms on daily functioning and quality of life. For multi-item scales, subjects respond to items using a Likert scale with responses ranging from 1 (strongly agree) to 5 (strongly disagree). Scores were computed by deriving the mean of the item sets and transforming the scale score on a continuum from 0 to 100 using a standard formula. Higher scores indicate a better quality of life.
Time frame: Baseline and up to 10 weeks
Change From Baseline in Informant-reported BRIEF-A T-scores at up to 10 Weeks
BRIEF-A is a validated 75-item questionnaire composed of three indexes (Global Executive Composite, Behavioral Recognition Index, and Metacognition Index). Items are rated 1 (never), 2 (sometimes), and 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
Time frame: Baseline and up to10 weeks
Change From Baseline in Subject-reported BRIEF-A T-scores at up to 10 Weeks
BRIEF-A is a validated 75-item questionnaire composed of three indexes (Global Executive Composite, Behavioral Recognition Index, and Metacognition Index). Global Executive Composite was reported as the Primary Outcome. Items are rated 1 (never), 2 (sometimes), and 3 (often). There is no range for a total score. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
Time frame: Baseline and up to 10 weeks
Change From Baseline in Subject-reported BRIEF-A Clinical Subscales T-scores at up to 10 Weeks
BRIEF-A clinical subscales items are rated 1 (never), 2 (sometimes), and 3 (often). There is no range for a total score. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
Time frame: Baseline and up to 10 weeks
Change From Baseline in Informant-reported BRIEF-A Clinical Subscales T-scores at up to 10 Weeks
BRIEF-A clinical subscales items are rated 1 (never), 2 (sometimes), and 3 (often). There is no range for a total score. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
Time frame: Baseline and up to 10 weeks
Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS) With Adult Prompts Total Score at up to 10 Weeks
The ADHD-RS consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. Lower scores indicate reduction in symptoms.
Time frame: Baseline and up to 10 weeks
Percent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Baseline
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)
Time frame: Baseline
Percent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at up to 10 Weeks
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)
Time frame: Up to 10 weeks post-dose
Percent of Participants With Improvement on Clinical Global Impression - Global Improvement (CGI-I) at up to 10 Weeks
Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.
Time frame: Up to 10 weeks post-dose
Change From Baseline in AIM-A Multi-Item Scales of Living With ADHD and General Well-being Score at up to 10 Weeks
The AIM-A was developed to assess impact of core ADHD symptoms on daily functioning and quality of life. For multi-item scales, subjects respond to items using a Likert scale with responses ranging from 1 (strongly agree) to 5 (strongly disagree). Scores were computed by deriving the mean of the item sets and transforming the scale score on a continuum from 0 to 100 using a standard formula. Higher scores indicate a better quality of life.
Time frame: Baseline and up to 10 weeks
Change From Baseline in AIM-A Quality of Life Questions 1 and 4 Scores at up to 10 Weeks
Question 1: 'On a scale of 1 to 10, how would you rate the overall quality of life right now?' It is rated on a scale of 1 (worst) to 10 (best). Higher scores representing a more positive rating. Question 4: 'How much do you agree with this statement: Over the past few weeks, I've had more good days than bad days?' This is rated on a scale of 1 (strongly agree) to 5 (strongly disagree). Lower scores represent better quality of life.
Time frame: Baseline and up to 10 weeks
Change From Baseline in Conner's Adult ADHD Rating Scale-Observer: Short Version (CAARS-O:S) ADHD Index T-score at up to 10 Weeks
The CAARS-O:S is an assessment tool with prompts provided to an observer who describes ADHD-related symptoms in an adult subject. The 26-item scale is scored on a 4-point scale from 0 (not at all) to 3 (very much, very frequently). There is no range for a total score. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
Time frame: Baseline and up to 10 weeks
Change From Baseline in CAARS-O:S Factor-derived Subscale T-scores at up to 10 Weeks
The CAARS-O:S is an assessment tool with prompts provided to an observer who describes ADHD-related symptoms in an adult subject. The 26-item scale is scored on a 4-point scale from 0 (not at all) to 3 (very much, very frequently). There is no range for a total score. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
Time frame: Baseline and up to 10 weeks
Change From Baseline in Adult ADHD Quality of Life (AAQoL) Scale Total Score at up to 10 Weeks
AAQoL is a validated 29-item scale consisting of 4 subscales. The AAQoL yields a total score and 4 subscale scores. Subjects rate each item on a 5-point Likert scale ranging from 1 (not at all/never) to 5 (extremely/very often). These scores are then transformed to a 0-100 point scale with higher scores indicating better quality of life.
Time frame: Baseline and up to 10 weeks
| Milestone | SPD489 | Placebo |
|---|---|---|
| Started | 79 | 80 |
| Completed | 62 | 53 |
| Not completed | 17 | 27 |
| Withdrew: Adverse event | 6 | 2 |
| Withdrew: Protocol violation | 4 | 3 |
| Withdrew: Withdrawal by subject | 3 | 8 |
| Withdrew: Lost to follow-up | 1 | 4 |
| Withdrew: Lack of efficacy | 0 | 7 |
| Withdrew: Sponsor decision | 1 | 1 |
| Withdrew: Non-compliance | 1 | 0 |
| Withdrew: Work schedule | 1 | 1 |
| Withdrew: Vacation | 0 | 1 |
BRIEF-A Global Executive Composite assesses behavioral aspects of executive function. Items are rated 1 (never), 2 (sometimes), and 3 (often). There is no range for a total score. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
| T-scores | SPD489 | Placebo |
|---|---|---|
| Change From Baseline in Subject-reported Behavior Rating Inventory of Executive Function - Adult Version Global Executive Composite T-score (BRIEF-A GEC T) at up to 10 Weeks | -22.3 ± 1.67 | -11.1 ± 1.72 |
The AIM-A was developed to assess impact of core ADHD symptoms on daily functioning and quality of life. For multi-item scales, subjects respond to items using a Likert scale with responses ranging from 1 (strongly agree) to 5 (strongly disagree). Scores were computed by deriving the mean of the item sets and transforming the scale score on a continuum from 0 to 100 using a standard formula. Higher scores indicate a better quality of life.
| Scores on a scale | SPD489 | Placebo |
|---|---|---|
| Performance and Daily Functioning | 38.8 ± 2.84 | 17.2 ± 2.91 |
| Impact of symptoms: Daily Interference | 30.6 ± 2.52 | 15.7 ± 2.58 |
| Impact of symptoms: Bother/Concern | 29.3 ± 2.53 | 15.8 ± 2.60 |
| Relationships/Communication | 21.2 ± 2.49 | 13.4 ± 2.56 |
BRIEF-A is a validated 75-item questionnaire composed of three indexes (Global Executive Composite, Behavioral Recognition Index, and Metacognition Index). Items are rated 1 (never), 2 (sometimes), and 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
| T-scores | SPD489 | Placebo |
|---|---|---|
| Global Executive Composite | -10.2 ± 1.06 | -5.3 ± 1.06 |
| Behavioral Regulation Index | -8.6 ± 1.04 | -5.5 ± 1.04 |
| Metacognition Index | -10.3 ± 1.07 | -4.6 ± 1.07 |
BRIEF-A is a validated 75-item questionnaire composed of three indexes (Global Executive Composite, Behavioral Recognition Index, and Metacognition Index). Global Executive Composite was reported as the Primary Outcome. Items are rated 1 (never), 2 (sometimes), and 3 (often). There is no range for a total score. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
| T-scores | SPD489 | Placebo |
|---|---|---|
| Behavioral Regulation Index | -17.5 ± 1.54 | -9.2 ± 1.58 |
| Metacognition Index | -22.8 ± 1.63 | -11.2 ± 1.67 |
BRIEF-A clinical subscales items are rated 1 (never), 2 (sometimes), and 3 (often). There is no range for a total score. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
| T-scores | SPD489 | Placebo |
|---|---|---|
| Inhibit | -17.8 ± 1.50 | -9.5 ± 1.54 |
| Shift | -14.5 ± 1.46 | -7.8 ± 1.50 |
| Emotional control | -10.9 ± 1.28 | -5.7 ± 1.31 |
| Self-monitor | -16.6 ± 1.44 | -8.4 ± 1.48 |
| Initiate | -17.9 ± 1.38 | -8.6 ± 1.41 |
| Working memory | -23.2 ± 1.67 | -11.9 ± 1.71 |
| Plan/Organize | -20.8 ± 1.58 | -9.9 ± 1.62 |
| Task monitor | -20.1 ± 1.64 | -10.8 ± 1.68 |
| Organization of materials | -16.5 ± 1.26 | -7.6 ± 1.30 |
BRIEF-A clinical subscales items are rated 1 (never), 2 (sometimes), and 3 (often). There is no range for a total score. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
| T-scores | SPD489 | Placebo |
|---|---|---|
| Inhibit | -10.2 ± 1.08 | -5.8 ± 1.08 |
| Shift | -9.1 ± 1.17 | -4.3 ± 1.17 |
| Emotional control | -5.9 ± 0.99 | -4.6 ± 0.99 |
| Self-monitor | -6.8 ± 1.04 | -4.6 ± 1.04 |
| Initiate | -8.6 ± 1.00 | -3.2 ± 1.00 |
| Working memory | -12.0 ± 1.22 | -5.7 ± 1.22 |
| Plan/Organize | -9.9 ± 1.07 | -5.0 ± 1.07 |
| Task monitor | -9.7 ± 1.21 | -3.4 ± 1.21 |
| Organization of materials | -6.2 ± 0.97 | -3.0 ± 0.97 |
The ADHD-RS consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. Lower scores indicate reduction in symptoms.
| Scores on a scale | SPD489 | Placebo |
|---|---|---|
| Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS) With Adult Prompts Total Score at up to 10 Weeks | -21.4 ± 1.35 | -10.3 ± 1.38 |
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)
| Percent of participants | SPD489 | Placebo |
|---|---|---|
| Normal, not at all ill | 0 | 0 |
| Borderline mentally ill | 0 | 0 |
| Mildly ill | 0 | 0 |
| Moderately ill | 48.1 | 42.7 |
| Markedly ill | 38.0 | 49.3 |
| Severely ill | 13.9 | 8.0 |
| Among the most extremely ill | 0 | 0 |
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)
| Percent of participants | SPD489 | Placebo |
|---|---|---|
| Normal, not at all ill | 13.9 | 6.7 |
| Borderline mentally ill | 38.0 | 16.0 |
| Mildly ill | 21.5 | 10.7 |
| Moderately ill | 15.2 | 37.3 |
| Markedly ill | 8.9 | 25.3 |
| Severely ill | 2.5 | 4.0 |
| Among the most extremely ill | 0 | 0 |
Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.
| Percent of participants | SPD489 | Placebo |
|---|---|---|
| Percent of Participants With Improvement on Clinical Global Impression - Global Improvement (CGI-I) at up to 10 Weeks | 78.5 | 34.7 |
The AIM-A was developed to assess impact of core ADHD symptoms on daily functioning and quality of life. For multi-item scales, subjects respond to items using a Likert scale with responses ranging from 1 (strongly agree) to 5 (strongly disagree). Scores were computed by deriving the mean of the item sets and transforming the scale score on a continuum from 0 to 100 using a standard formula. Higher scores indicate a better quality of life.
| Scores on a scale | SPD489 | Placebo |
|---|---|---|
| Living with ADHD | 14.0 ± 1.30 | 4.9 ± 1.33 |
| General Well-being | 19.7 ± 1.69 | 9.0 ± 1.73 |
Question 1: 'On a scale of 1 to 10, how would you rate the overall quality of life right now?' It is rated on a scale of 1 (worst) to 10 (best). Higher scores representing a more positive rating. Question 4: 'How much do you agree with this statement: Over the past few weeks, I've had more good days than bad days?' This is rated on a scale of 1 (strongly agree) to 5 (strongly disagree). Lower scores represent better quality of life.
| Scores on a scale | SPD489 | Placebo |
|---|---|---|
| Question 1 | 1.6 ± 0.16 | 1.0 ± 0.16 |
| Question 4 | -1.0 ± 0.11 | -0.4 ± 0.11 |
The CAARS-O:S is an assessment tool with prompts provided to an observer who describes ADHD-related symptoms in an adult subject. The 26-item scale is scored on a 4-point scale from 0 (not at all) to 3 (very much, very frequently). There is no range for a total score. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
| T-scores | SPD489 | Placebo |
|---|---|---|
| Change From Baseline in Conner's Adult ADHD Rating Scale-Observer: Short Version (CAARS-O:S) ADHD Index T-score at up to 10 Weeks | -11.3 ± 1.24 | -5.8 ± 1.24 |
The CAARS-O:S is an assessment tool with prompts provided to an observer who describes ADHD-related symptoms in an adult subject. The 26-item scale is scored on a 4-point scale from 0 (not at all) to 3 (very much, very frequently). There is no range for a total score. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
| T-scores | SPD489 | Placebo |
|---|---|---|
| Inattention/Memory Problems | -10.0 ± 1.12 | -4.9 ± 1.12 |
| Hyperactivity/Restlessness | -9.1 ± 1.20 | -5.0 ± 1.20 |
| Impulsivity/Emotional Liability | -8.0 ± 1.01 | -4.0 ± 1.01 |
| Problems with Self-concept | -7.7 ± 1.10 | -3.3 ± 1.10 |
AAQoL is a validated 29-item scale consisting of 4 subscales. The AAQoL yields a total score and 4 subscale scores. Subjects rate each item on a 5-point Likert scale ranging from 1 (not at all/never) to 5 (extremely/very often). These scores are then transformed to a 0-100 point scale with higher scores indicating better quality of life.
| Scores on a scale | SPD489 | Placebo |
|---|---|---|
| Life Productivity | 38.0 ± 4.34 | 17.0 ± 4.51 |
| Psychological Health | 19.3 ± 3.61 | 7.2 ± 3.74 |
| Life Outlook | 18.5 ± 2.85 | 6.0 ± 2.96 |
| Relationships | 17.1 ± 3.69 | 9.8 ± 3.83 |
| Total Score | 25.9 ± 3.04 | 11.1 ± 3.16 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SPD489 | — | 0/79 (0%) | 62/79 (78.5%) |
| Placebo | — | 0/80 (0%) | 41/80 (51.3%) |
| Event | SPD489 | Placebo |
|---|---|---|
| Decreased ApetiteMetabolism and nutrition disorders | 26/79 | 5/80 |
| Dry MouthGastrointestinal disorders | 25/79 | 6/80 |
| HeadacheNervous system disorders | 20/79 | 2/80 |
| Feeling JitteryGeneral disorders | 10/79 | 0/80 |
| InsomniaPsychiatric disorders | 10/79 | 3/80 |
| IrritabilityGeneral disorders | 8/79 | 3/80 |
| Weight DecreasedInvestigations | 8/79 | 0/80 |
| Initial InsomniaPsychiatric disorders | 8/79 | 5/80 |
| DiarrheaGastrointestinal disorders | 6/79 | 2/80 |
| FatigueGeneral disorders | 6/79 | 3/80 |
| Age, Continuous(years) | SPD489 | Placebo | Total |
|---|---|---|---|
| Mean | 34.2 ± 10.58 | 34.9 ± 11.02 | 34.6 ± 10.77 |
| Age, Customized(Participants) | SPD489 | Placebo | Total |
|---|---|---|---|
| <18 years | 0 | 0 | 0 |
| 18 to 55 years | 79 | 80 | 159 |
| >55 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | SPD489 | Placebo | Total |
|---|---|---|---|
| Female | 39 | 37 | 76 |
| Male | 40 | 43 | 83 |
| Region of Enrollment(Participants) | SPD489 | Placebo | Total |
|---|---|---|---|
| United States | 79 | 80 | 159 |
Ran from May 2010 to primary completion in Nov 2010, 6 months.
Results were first posted in Feb 2012, 1 year 2 months after primary completion.
Of 62 phase 4 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 70. This study's 6 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lisdexamfetamine
Attention Deficit Disorder with Hyperactivity →